A prospective observational study to investigate the efficacy of palliative hypofractionated radiotherapy (QUAD shot) for advanced head and neck squamous cell carcinoma

A prospective observational study to investigate the efficacy of palliative hypofractionated radiotherapy (QUAD shot) for advanced head and neck squamous cell carcinoma - A prospective observational study to investigate the efficacy of palliative hypofractionated radiotherapy (QUAD shot) for advanced head and neck squamous cell carcinoma

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000055558

Enrollment

Registered

2024-10-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced head and neck squamous cell carcinoma (UICC 8th edition stage III or IV) scheduled for palliative hypofractionated radiotherapy using 3D-CRT or IMRT (QUAD Shot; 14-14.8 Gy/4 fractions/2 days/course, with a rest period of 3-6 weeks, total of 3 courses).

Exclusion criteria

Exclusion criteria: Patients who refused radiation therapy

Design outcomes

Primary

Measure	Time frame
3. Tumor shrinkage on imaging, tumor shrinkage on physical findings, overall survival, progression-free survival, QOL score, and adverse events one month after the end of the course.	—

Countries

Japan

Contacts

Public ContactOsamu Tanaka

Asahi Univ. Hospital Radiation Oncology

c.bluered@gmail.com058-253-8001

Outcome results